CTNM vs. SBTX, XOMA, AQST, VTYX, KMDA, ERAS, CRMD, TERN, ORGO, and VRCA
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Silverback Therapeutics (SBTX), XOMA (XOMA), Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX), Kamada (KMDA), Erasca (ERAS), CorMedix (CRMD), Terns Pharmaceuticals (TERN), Organogenesis (ORGO), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Contineum Therapeutics had 6 more articles in the media than Silverback Therapeutics. MarketBeat recorded 7 mentions for Contineum Therapeutics and 1 mentions for Silverback Therapeutics. Contineum Therapeutics' average media sentiment score of 0.50 beat Silverback Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.
Silverback Therapeutics received 15 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
Contineum Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity.
Contineum Therapeutics presently has a consensus price target of $28.00, indicating a potential upside of 81.23%. Given Contineum Therapeutics' higher probable upside, equities research analysts plainly believe Contineum Therapeutics is more favorable than Silverback Therapeutics.
Summary
Contineum Therapeutics beats Silverback Therapeutics on 7 of the 10 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
